ArticleMolecular medicine (Cambridge, Mass.)2025
Isoimperatorin, a natural furanocoumarin, ameliorates ulcerative colitis by inducing Treg cell generation and promoting mucosal healing.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Focal adhesion kinase: A promising regulator of colitis-associated healing.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundUlcerative colitis (UC), an autoimmune disorder characterized by chronic intestinal inflammation, primarily targets the colonic mucosa. Isoimperatorin is a natural furanocoumarin compound with a variety of pharmacological activities. However, its therapeutic potential and underlying mechanisms in UC pathogenesis remain to be elucidated.
methodsMice were administered 2.5% dextran sulfate sodium (DSS) ad libitum to construct a colitis model, and isoimperatorin was given by gavage to evaluate its efficacy. Flow cytometry and qPCR were employed to assess the effect of isoimperatorin on Treg cell generation. Tissue immunofluorescence and Western blot were used to investigate the effects of isoimperatorin on the repair of damaged intestinal barrier. Cell scratching and migration were used to examine the effects of isoimperatorin on wound healing and cell migration. Finally, a Treg cell depletion assay was implemented to verify the Treg cell-dependent effect of isoimperatorin on repairing intestinal barrier injury to ameliorate UC.
resultsOral gavage administration of isoimperatorin (20, 40 mg/kg) significantly improved disease symptoms in UC mice. Isoimperatorin treatment elevated the percentage of Treg cells but had no significant effect on the proportion of Th17 cells in mesenteric lymph node tissues. Isoimperatorin upregulated the expression levels of factors related to mucosal healing and upregulated the expression levels of proteins related to the integrity of the intestinal epithelial barrier. Additionally, isoimperatorin (1, 3 µM) accelerated the migration of colon epithelial cells to facilitate wound healing and also induced the generation of Treg cells in vitro. Finally, Treg cell depletion markedly attenuated isoimperatorin's therapeutic efficacy in intestinal barrier repair and UC amelioration, indicating a Treg cell-dependent mechanism of action.
conclusionsIsoimperatorin promotes intestinal mucosal healing and thus improves UC disease symptoms by inducing Treg cell generation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.